查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球乳癌診斷市場 - 2023-2030
市場調查報告書
商品編碼
1348009

全球乳癌診斷市場 - 2023-2030

Global Breast Cancer Diagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

根據世界衛生組織的數據，乳腺癌是全球最常見的癌症類型。據估計，登記的診斷性乳癌病例數將從2020 年的約230 萬例新診斷病例攀升，預計到2040 年將超過300 萬例。浸潤性乳管癌是最常見的乳癌類型，始於2020年。乳房並擴散到附近的組織。每 10 例乳癌病例中，有 7 至 8 例為侵襲性乳管癌。

老化是女性乳癌最常見的原因之一。根據美國癌症協會統計，2022 年 2 月，每 8 名女性中有 1 名年齡小於 45 歲，每 3 名女性中有 2 名年齡在 55 歲或以上。

動力學

診斷技術的進步

與傳統的乳房X光檢查相比，乳癌篩檢的進步提供了更好的結果。人工智慧與深度學習的結合使乳癌篩檢更加準確可靠。機器學習與診斷技術的整合可以為乳癌患者帶來更準確的治療結果。

例如，2022 年 1 月，杜克大學研究人員創建了一個人工智慧 (AI) 平台，用於分析乳房 X 光攝影掃描中潛在的癌性病變，並確定患者是否應該接受侵入性活體組織切片。這種人工智慧有助於檢測可疑病變，可用於培訓學生如何閱讀乳房X光檢查影像，並可以幫助醫生做出醫療保健決策。此外，這種人工智慧技術可用於做出明智的決策。

此外，2023年2月，FathomX Pte Ltd.推出了利用人工智慧和深度學習的乳房X光檢查，以進行早期乳癌診斷的研發。在基於乳房X光檢查的乳癌篩檢中，該公司專有的人工智慧技術可以更快速、更準確地檢測X光影像上的癌組織跡象。

此外，乳癌的盛行率、早期診斷的需求和產品核准是未來一段時間推動市場的幾個因素。

假陽性結果

假陽性結果在年輕、乳房緻密、做過乳房活體組織切片、家族中患有乳腺癌或正在服用雌激素的女性中更常見。在10年內每年接受乳房X光檢查的女性中，約有一半會在某個時候出現假陽性結果。過去的病史將他們假陽性發現的幾率降低了大約一半。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按癌症類型分類
  • 按測試類型分類區隔
  • 傳播區隔
  • 階段區隔
  • 最終使用者區隔
  • 按地區分類區隔

第 4 章：動力學

  • 影響因素
    • 動力
      • 診斷技術的進步
    • 限制
      • 假陽性結果
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 流行病學
  • 2022-2030 年美國、歐盟五國、日本、中國和印度進行的乳癌檢測數量 在深度資料庫查看
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按癌症類型

  • 浸潤性小葉乳癌
  • 乳管原位癌（DCIS）
  • 三陰性乳癌
  • 發炎性乳癌
  • 其他

第 8 章：按測試類型

  • 臨床乳房檢查
  • 影像學檢查
    • 核磁共振成像
    • 超音波
    • 寵物
    • 其他
  • 血液檢查
  • 活體組織切片
      • 切除活體組織切片
      • 切開活體組織切片
      • 核心切片
      • 細針抽吸 (FNA) 活體組織切片
      • 其他
  • 其他

第 9 章：按傳播

  • 當地的
  • 區域性
  • 遙遠

第 10 章：按階段

  • 階段I
  • 第二階段
  • 第三階段
  • 第四階段

第 11 章：最終用戶

  • 醫院和診所
  • 癌症診斷中心
  • 癌症研究機構
  • 醫學研究中心和研究所
  • 門診手術中心
  • 其他

第 12 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第13章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 14 章：公司簡介

  • Siemens Healthineers AG
    • 公司簡介
    • 產品類型組合和描述
    • 財務概覽
    • 主要進展
  • Kheiron Medical Technologies
  • Bio-Rad Laboratories
  • Hologic, Inc.
  • Quest Diagnostics Incorporated
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Illumina, Inc.
  • Metaltronica SpA
  • Carestream Health

第 15 章：附錄

簡介目錄
Product Code: CD2142

Overview

According to the World Health Organization, breast cancer is the most commonly diagnosed type of cancer globally. The number of registered diagnostic breast cancer cases ase count has been estimated to climb from about 2.3 million new diagnoses in 2020 and is expected to more than 3 million in 2040. Invasive ductal carcinoma is the most common type of breast cancer, which starts in the mammary glands and spreads to nearby tissue. For every 10 breast cancer cases, 7 to 8 are invasive ductal carcinoma.

Aging is one of the most prevalent causes of breast cancer in women. According to the American Cancer Society, in February 2022, 1 out of 8 women younger than 45 years, 2 out of 3 in 55 years or older.

Dynamics

Advancements in diagnostic technologies

Advancements in breast cancer screening provide better outcomes when compared to conventional mammography. Integrating Artificial intelligence and deep learning makes breast cancer screening more accurate and reliable. Integration of machine learning with diagnostic techniques lead to more accurate treatment outcomes in breast cancer patients.

For instance, in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians make health care decisions. Furthermore, this AI technology could be used for making wise decisions.

Furthermore, in February 2023, FathomX Pte Ltd. launched mammography using AI and deep learning to conduct R&D for early breast cancer diagnosis. In mammography-based breast cancer screening, the company's proprietary AI technology makes it possible to detect signs of cancerous tissue on X-ray images more quickly and accurately.

Furthermore, the prevalence of breast cancer, the need for early diagnosis, and product approvals are a few factors that drive the market in the forthcoming period.

False positive results

False-positive results are more common in women who are younger, have dense breasts, have had breast biopsies, have breast cancer in the family, or are taking estrogen. About half of the women getting annual mammograms over a 10-year period will have a false-positive finding at some point. Past history reduces their odds of a false-positive finding by about half.

Segment Analysis

The global breast cancer diagnostics is segmented based on cancer type, test type, spread, stage, end user, and region.

Early detection is crucial in improving breast cancer treatment. Innovations in screening methods have played a pivotal role in detecting breast cancer at its earliest stages. Digital mammography and tomosynthesis have replaced traditional film mammography, providing more precise and detailed images. Unlike conventional mammography, digital mammography and contrast-enhanced mammography offer better diagnosis and, thus, better treatment.

For instance, in January 2023, Bayer's iodine-based contrast agent Ultravist-300, -370 received the green light for indication extension for contrast-enhanced mammography (CEM) in a European Workshare Procedure. CEM is an emerging modality combining digital mammography with the administration of a contrast agent. Strategically expands Bayer's portfolio in breast imaging, including contrast agents and injectors. These factors are likely to increase the mammography segment in the forecast period.

Geographical Analysis

North America dominated the breast cancer diagnostics market in 2022. It is estimated to hold the largest market size over the forecast period (2022-2029) owing to rising breast cancer cases and increasing technological advancements in cancer diagnosis. For instance, as per the statistics from Breastcancer.org, as of January 2022, over 3.8 million women with a history of breast cancer in the U.S., and about 1 in 8 U.S. women (about 13%) in their lifetime would develop invasive breast cancer.

In 2022, around 287,850 new cases of invasive breast cancer were diagnosed in U.S. women, also 51,400 new cases of non-invasive (in situ) breast cancer. In 2022 about 2,710 new cases of invasive breast cancer were detected in men. In 2022, over about 43,250 women in the U.S. died from breast cancer. In addition, increasing development by manufacturers in breast cancer diagnostics is driving the market growth in this region.

COVID-19 Impact Analysis

COVID-19 has negatively impacted the global market during the outbreak since, to prevent the COVID-19 infection, various restrictions and regulations were employed, making it difficult for people to perform mammography and other breast cancer diagnostic tests affecting the market. Furthermore, a retrospective study of cases diagnosed by a reference service in the public health system of Campinas, SP, Brazil, concluded that amid the COVID-19 pandemic, breast cancer diagnoses declined. Moreover, the cases detected indicated a worsened prognosis as early detection was not performed.

Many healthcare facilities postponed non-urgent procedures and screenings, which affected the number of women getting regular tests. Additionally, fears of contracting the virus in healthcare settings and mobility restrictions further reduced screening rates. Due to these above factors, the market has seen a decline rate during the pandemic period.

By Cancer Type

  • Invasive lobular breast cancer
  • Ductal carcinoma in situ (DCIS)
  • Triple-negative breast cancer
  • Inflammatory breast cancer
  • Others

By Test Type

  • Clinical Breast Exam
  • Imaging Tests
    • Mammogram
    • MRI
    • Ultrasound
    • PET
    • Others
  • Blood Tests
  • Biopsies
    • Excisional biopsy
    • Incisional biopsy
    • Core biopsy
    • Fine-needle aspiration (FNA) biopsy
    • Others
  • Others

By Spread

  • Local
  • Regional
  • Distant

By Stage

  • I
  • II
  • III
  • IV

By End User

  • Hospitals and Clinics
  • Cancer Diagnostic Centers
  • Cancer Research Institutes
  • Medical Research Centers and Institutes
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the breast cancer diagnostics market include: Siemens Healthineers AG, Kheiron Medical Technologies, Bio-Rad Laboratories, Hologic, Inc., Quest Diagnostics Incorporated, FUJIFILM Holdings Corporation, GE Healthcare, Illumina, Inc., Metaltronica SpA, and Carestream Health among others.

Key Developments

  • In May 2022, the U.S. Department of Health and Human Services (HHS), declared the availability of US$ 5 million for community health centers, funded by HHS's Health Resources and Services Administration, to increase equitable access to life-saving breast cancer screenings.
  • In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography).

Why Purchase the Report?

  • To visualize the global breast cancer diagnostics segmentation based on cancer type, test type, spread, stage, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of breast cancer diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global breast cancer diagnostics market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Spread
  • 3.4. Snippet by Stage
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Diagnostic Technologies
    • 4.1.2. Restraints
      • 4.1.2.1. False Positive Results
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Epidemiology
  • 5.6. Number of Breast Cancer Tests Conducted in US, EU5, Japan, China and India 2022-2030
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Invasive lobular breast cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ductal carcinoma in situ (DCIS)
  • 7.4. Triple-negative breast cancer
  • 7.5. Inflammatory breast cancer
  • 7.6. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type
  • 8.2. Clinical Breast Exam*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Imaging Tests
      • 8.3.1.1. MRI
      • 8.3.1.2. Ultrasound
      • 8.3.1.3. PET
      • 8.3.1.4. Others
  • 8.4. Blood Tests
  • 8.5. Biopsies
      • 8.5.1.1. Excisional biopsy
      • 8.5.1.2. Incisional biopsy
      • 8.5.1.3. Core biopsy
      • 8.5.1.4. Fine-needle aspiration (FNA) biopsy
      • 8.5.1.5. Others
  • 8.6. Others

9. By Spread

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 9.1.2. Market Attractiveness Index, By Spread
  • 9.2. Local*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Regional
  • 9.4. Distant

10. By Stage

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 10.1.2. Market Attractiveness Index, By Stage
  • 10.2. Stage I*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Stage II
  • 10.4. Stage III
  • 10.5. Stage IV

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Hospitals and Clinics*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Cancer Diagnostic Centers
  • 11.4. Cancer Research Institutes
  • 11.5. Medical Research Centers and Institutes
  • 11.6. Ambulatory Surgical Centers
  • 11.7. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Siemens Healthineers AG
    • 14.1.1. Company Overview
    • 14.1.2. Product Type Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Kheiron Medical Technologies
  • 14.3. Bio-Rad Laboratories
  • 14.4. Hologic, Inc.
  • 14.5. Quest Diagnostics Incorporated
  • 14.6. FUJIFILM Holdings Corporation
  • 14.7. GE Healthcare
  • 14.8. Illumina, Inc.
  • 14.9. Metaltronica SpA
  • 14.10. Carestream Health

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us